Antibody Drug Conjugates

Tampa – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) reported a second-quarter 2026 net loss of $4.8 million, up from $1.9 million a year earlier, as research and development spending tripled to $2.1 million ahead of a planned Phase 1 start for its lead antibody drug conjugate (ADC), AKTX-101, in mid-2027.

Akari raised $8.6 million gross in the quarter, lifting cash to $7.7 million

The company closed a private placement with $5.5 million in gross proceeds and booked $3.1 million in gross proceeds from warrant exercises. Total gross financing was approximately $8.6 million, with approximately $8.0 million in net proceeds. Cash stood at $7.7 million on June 30, 2026, up from $5.2 million at December 31, 2025. Akari said long-term strategic investors led the financing.

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is targeting a First-In-Human trial of its lead antibody drug conjugate (ADC), AKTX-101, by mid-2027, after starting IND-enabling studies. The company laid out its investment case in the Virtual Investor "Why Now" on-demand conference.

CEO Abizer Gaslightwala argued that now is a pivotal time for Akari. He cited a fast-changing ADC landscape and rising industry demand for differentiated payload technologies.

Akari pitches PH1 splicing payload as alternative to conventional ADC toxins

Akari's proprietary PH1 platform is a spliceosome modulator designed to disrupt RNA splicing inside cancer cells. Current ADCs rely on microtubule inhibitors and DNA-damaging agents. According to the company, PH1 is meant to address limitations of those conventional payloads.